Envista (NVST)
(Delayed Data from NYSE)
$18.83 USD
-0.17 (-0.89%)
Updated May 8, 2024 04:00 PM ET
After-Market: $18.84 +0.01 (0.05%) 7:58 PM ET
4-Sell of 5 4
C Value C Growth C Momentum C VGM
Envista (NVST) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$21.41 | $30.00 | $17.00 | 12.68% |
Price Target
Based on short-term price targets offered by 11 analysts, the average price target for Envista comes to $21.41. The forecasts range from a low of $17.00 to a high of $30.00. The average price target represents an increase of 12.68% from the last closing price of $19.00.
Analyst Price Targets (11)
Broker Rating
Envista currently has an average brokerage recommendation (ABR) of 2.83 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 12 brokerage firms. The current ABR compares to an ABR of 2.67 a month ago based on 12 recommendations.
Of the 12 recommendations deriving the current ABR, three are Strong Buy, representing 25% of all recommendations. A month ago, Strong Buy represented 33.33%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 3 | 3 | 4 | 4 | 4 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 7 | 7 | 6 | 6 | 6 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 2 | 2 | 2 | 2 | 1 |
ABR | 2.83 | 2.83 | 2.67 | 2.67 | 2.45 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
5/2/2024 | SVB Securities | Michael Cherny | Strong Sell | Strong Sell |
5/2/2024 | Robert W. Baird & Co. | Jeffrey D Johnson | Hold | Hold |
5/2/2024 | Needham & Company | David Saxon | Hold | Hold |
2/8/2024 | William Blair | Brandon Vazquez | Strong Buy | Hold |
2/8/2024 | Piper Sandler | Jason Bednar | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.83 |
ABR (Last week) | 2.83 |
# of Recs in ABR | 12 |
Average Target Price | $21.41 |
LT Growth Rate | 1.00% |
Industry | Medical - Products |
Industry Rank by ABR | 99 of 252 |
Current Quarter EPS Est: | 0.31 |